Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Thyroid Cancer
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Situation of the tumor at first-diagnosis
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- •Patients who agree to participate and are able to understand the information sheet and sign the informed consent
Exclusion Criteria
- •Patients under 18 years of age.
- •Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- •Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
Outcomes
Primary Outcomes
Situation of the tumor at first-diagnosis
Time Frame: Baseline
Local tumor, locoregional tumor or metastatic disease.
Tumor-Node-Metastasis classification
Time Frame: Baseline
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Tumor Stage
Time Frame: Baseline
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Hystopathological characteristics of the tumor
Time Frame: Baseline
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Secondary Outcomes
- Number of patients with P53 mutation(12 months)
- Patient situation at the end of treatment(12 months)
- Number of patients with RAS mutation(12 months)
- Number of patients with BRAF mutation(12 months)
- Number of patients with RET mutation(12 months)
- Number of patients with PI3K mutation(12 months)
- Number of patients with PAX8/PAR mutation(12 months)
- Number of patients with PTEN mutation(12 months)